Daclizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022: New ... SBWire (press release) Boston, MA -- (SBWIRE) -- 07/03/2013 -- GlobalData has released its new PharmaPoint Drug Evaluation report, "Daclizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological ... |
